Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19CART for Relapsed/Refractory B-cell Malignancies
NCT02813837Phase 1Unknown
- Sponsor
- Innovative Cellular Therapeutics
- Start
- Jun 2015
- Primary completion
- Jan 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19 CAR-T cells in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), sponsored by Innovative Cellular Therapeutics. Primary endpoint: Occurrence of study related adverse events at 12 months. Status: unknown.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02813837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02813837.